DBV Technologies | DBVT - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amarin USD 122.8M 25.08M 2025-09
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
DBV Technologies USD 69.84M 33.37M 2025-09
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Galectin Therapeutics USD 25.6M 2.04M 2024-06
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Incyte USD 3.58B 650.78M 2025-12
Insmed USD 510.44M 175.68M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
PTC Therapeutics USD 984.65M 312.03M 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
United Therapeutics USD 1.56B 217M 2025-12